DiabetOmics Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 46
Employees
  • Latest Deal Type
  • Series D
  • Latest Deal Amount
  • $35M
Latest Deal Amount
  • Investors
  • 4

DiabetOmics General Information

Description

Developer of applications and technology intended for point-of-care risk assessment tests for diabetes and women's health disorders. The company's technology includes a saliva based test that measures total saliva glycosylated protein levels to estimate recent average blood glucose levels and also offers the pregnancy metabolic profile to estimate the risk of preeclampsia and gestational diabetes in expectant mothers by measuring the level of glycosylated fibronectin in maternal blood to help in the treatment of gestational diabetes profile and personalized wellness profile with laboratory tests to identify problem areas, enabling biomarkers to estimate the risk of developing juvenile diabetes and its detection.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Services
Decision/Risk Analysis
Primary Office
  • 2345 North East Overlook Drive
  • Suite 140
  • Hillsboro, OR 97006
  • United States
+1 (503) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

DiabetOmics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series D) 19-Jan-2018 $35M 000.00 00000 Completed Generating Revenue
4. Later Stage VC (Series C1) 12-Mar-2015 000 000.00 0000 Completed Generating Revenue
3. Later Stage VC (Series C) 24-Oct-2014 0000 000.00 0000 Completed Generating Revenue
2. Grant 31-Jul-2013 $733K $4.2M Completed Generating Revenue
1. Early Stage VC (Series A) 11-Oct-2011 $4.2M $4.2M 000 Completed Generating Revenue
To view DiabetOmics’s complete valuation and funding history, request access »

DiabetOmics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 0,000,000 000.00 000.00 00 000.00 00.000
Series C1 000,000 000.0 000.0 00 000.0 0.000
Series C 0,000,000 000.00 000.00 00 000.00 00.000
Series B 1,000,000 $9.39 $9.39 1x $9.39 13.48%
Series A 2,000,000 $2.5 $2.5 1x $2.5 26.95%
To view DiabetOmics’s complete cap table history, request access »

DiabetOmics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of applications and technology intended for point-of-care risk assessment tests for diabetes and women's healt
Diagnostic Equipment
Hillsboro, OR
46 As of 2021
000.00
0000 0000-00-00
00000000000 000.00

00000 00

elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su
0000000000 000000000
Bengaluru, India
000 As of 0000
000.00
00000 00000 000.00

00000000

e cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cu
00000 0000000000 00000000
Hyderabad, India
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DiabetOmics Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Forus Health Venture Capital-Backed Bengaluru, India 000 000.00 00000 00000 000.00
0000000000 Accelerator/Incubator Backed Hyderabad, India 000000000000
You’re viewing 2 of 2 competitors. Get the full list »

DiabetOmics Executive Team (10)

Name Title Board Seat Contact Info
Srinivasa Nagalla MD Co-Founder, Chief Executive Officer, Board Member & President
Barbara Chiapuzio Chief Financial Officer
Charles Roberts Ph.D Co-Founder, Vice President & Chief Science Officer
Paturi Rao Ph.D Co-Founder, Chief Medical Officer, Vice President & Board Member
Steven Kazmierczak Ph.D Vice President & Director of Clinical Laboratory
You’re viewing 5 of 10 executive team members. Get the full list »

DiabetOmics Board Members (5)

Name Representing Role Since
Bobba Venkatadri VenturEast Board Member 000 0000
Chris Dudley Self Board Member 000 0000
Karl Miller Jr. Rogue Venture Partners Board Member 000 0000
Robert Gootee Self Board Member 000 0000
Varaprasad Reddy Self Board Member 000 0000
To view DiabetOmics’s complete board members history, request access »

DiabetOmics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DiabetOmics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Varaprasad Reddy Angel (individual) Minority 000 0000 000000 0
VenturEast Venture Capital Minority 000 0000 000000 0
Oregon Venture Fund Venture Capital Minority 000 0000 000000 0
Rogue Venture Partners Venture Capital Minority 000 0000 000000 0
To view DiabetOmics’s complete investors history, request access »